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All therapeutically used sodium channel inhibitor drugs
seem to act similarly: in a use-dependent and state-
dependent manner. These properties, however, can be
caused by multiple mechanisms, as we and others have
previously shown [1]. The two major hypotheses that
explain use- and state-dependent inhibition are the MRH
[2] and the GRH [3]. In this study we investigated which
hypothesis better describes inhibition by various drugs,
and whether drugs can be classified based on this aspect
of their mechanism of action. We assumed that the two
hypotheses are not mutually exclusive, and speculated
that both altered affinity (as predicted by the MRH) and
altered accessibility (as predicted by the GRH) to the inac-
tivated state can be expressed as changes in association
and dissociation rates upon conformational transition.
We developed a method to test the relative contribution of
affinity and accessibility in the effect of the drugs based on
the degree of inhibition (reflecting affinity) and the time
constant of the onset of inhibition (reflecting accessibil-
ity) as a function of changes in the voltage protocol. We
tested the method by simulations and found that original
parameters of a simulated drug can be deduced using the
method. Experiments using 12 fast-inactivated state-pre-
ferring use-dependent sodium channel inhibitors suggest
significant differences in this aspect of the mechanism.
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